Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2024-10-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 华兰生物工程股份有限公司, detailing the decisions made at the 14th meeting of the 8th board, including approval of the 2024 Q3 report and stock incentive plan matters. It includes voting results and references to where the full Q3 report is published, but does not contain the full financial report itself. The document is short (1031 characters) and serves as an announcement of board decisions rather than a full report. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2024-10-29 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It contains specific financial data such as opening balances, amounts occupied, interest, repayments, and closing balances for various related parties and subsidiaries. The document is focused on financial data for a half-year period and is not a brief announcement or a certification. It is not a full annual report but rather a report covering a period shorter than a full fiscal year with substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 2545 characters, which is sufficient for a substantive report rather than a mere announcement. H1 2024
2024-08-29 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "华兰生物工程股份有限公司2024 年半年度报告全文" which translates to "Hualan Biological Engineering Co., Ltd. 2024 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, financial indicators, and other comprehensive information typical of a semi-annual financial report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes actual financial statements, performance metrics, and management commentary for the half-year period ending June 30, 2024. This matches the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-29 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and shareholder information. It also discusses company operations and product pricing adjustments during the reporting period. The document length is 4065 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it qualifies as an Interim / Quarterly Report (IR) rather than a mere announcement or summary. The presence of detailed financial metrics and business commentary confirms it is a financial report for a period shorter than a full fiscal year. H1 2024
2024-08-29 Chinese
关于全资子公司获批设置单采血浆站的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (523 characters) regarding the approval for the company's wholly-owned subsidiary to set up plasma collection stations. It includes regulatory approval references and states the company will disclose further information as progress occurs. There is no financial data, no report attached or referenced as published, and no mention of voting results or management changes. This fits the category of a general regulatory announcement about operational developments, best classified as a Regulatory Filing (RNS).
2024-08-23 Chinese
关于董事长、实际控制人、部分董事增持公司股份暨董事长、实际控制人、部分董事、高级管理人员后续增持计划的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the increase in shareholdings by the company's chairman, actual controller, some directors, and senior management. It details the number of shares held before and after the increase, the planned future share purchases, the purpose of the share increase, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or detailed financial analysis. The document focuses on insider share transactions and plans for further share purchases by insiders. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3590 characters, which is relatively short but contains substantive information about insider share dealings, not just an announcement of a report. Therefore, the correct classification is DIRS with high confidence.
2024-07-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.